Related Experiment Videos
Studies on the interaction between fibrates and statins using human hepatic microsomes.
Hideki Fujino1, Syunsuke Shimada, Iwao Yamada
1Tokyo New Drug Research Laboratories I, Kowa Company Ltd., Higashimurayama, Tokyo, Japan. h-fujino@kowa.co.jp
Arzneimittel-Forschung
|December 3, 2003
Summary
Gemfibrozil inhibits statin metabolism, increasing plasma concentrations. This drug interaction, particularly with CYP2C9, highlights potential risks when combining gemfibrozil with statins.
Area of Science:
- Pharmacology
- Drug Metabolism
- Medicinal Chemistry
Background:
- Drug-drug interactions between fibrates and statins can alter patient outcomes.
- Understanding the specific mechanisms is crucial for safe co-administration.
Purpose of the Study:
- To investigate the in vitro drug-drug interaction mechanisms between fibrates and statins.
- To elucidate the role of gemfibrozil in statin metabolism and protein binding.
Main Methods:
- In vitro experiments involving coincubation of fibrates and statins in human plasma.
- Analysis of statin metabolism inhibition and protein displacement.
- Investigation of gemfibrozil metabolic profile and its interaction with cytochrome P enzymes.
Main Results:
- Pitavastatin did not displace fibrates from plasma protein binding.
- Gemfibrozil significantly inhibited the metabolism of cerivastatin and atorvastatin.
- Gemfibrozil, metabolized by CYP2C9, showed potent inhibition of CYP-mediated metabolism, unlike other fibrates.
Conclusions:
- Gemfibrozil's inhibition of CYP-mediated metabolism is a key factor in the increased plasma concentrations observed with co-administered statins.
- The drug interaction mechanism is not fully elucidated but involves CYP enzyme inhibition.